No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments
In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.